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MaAnthracycline compounds are major culprits in chemotherapy-induced cardiotoxicity, which is the chief limiting factor in
delivering optimal chemotherapy to cancer patients. Although extensive efforts have been devoted to identifying stra-
tegies to prevent anthracycline-induced cardiotoxicity, there is little consensus regarding the best approach. Recent
advances in basic mechanisms of anthracycline-induced cardiotoxicity provided a uniﬁed theory to explain the old
reactive-oxygen species hypothesis and identiﬁed topoisomerase 2b as the primary molecular target for cardioprotection.
This review outlines current strategies for primary and secondary prevention of anthracycline-induced cardiotoxicity
resulting from newly recognized molecular mechanisms and identiﬁes knowledge gaps requiring further
investigation. (J Am Coll Cardiol 2014;64:938–45) © 2014 by the American College of Cardiology Foundation.T he U.S. National Cancer Institute estimatesthat at least 13.7 million cancer survivorswere alive in the United States in 2012 and
that this number will approach 18 million by 2022
(1). A total of 67% of adults diagnosed with cancer
today will be alive in 5 years, and 75% of children
diagnosed with cancer today will be alive in 10 years.
Cancer chemotherapy or radiotherapy can cause
short- and long-term cardiovascular complications.
In a U.S. National Health and Nutrition Examination
survey of 1,807 cancer survivors followed for 7 years,
33% died of heart diseases and 51% of cancer (2).
The primary cause of chemotherapy-induced
cardiotoxicity is anthracycline compounds, which
are used extensively to treat lymphoma, sarcoma,
breast cancer, and pediatric leukemia (Table 1).
Despite efforts to identify risk factors, develop
less-toxic derivatives, and detect subclinical toxicity
earlier, there is no consensus on the best approach
to prevent anthracycline-induced cardiotoxicity.
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better cardioprotective strategies.
RISK FACTORS FOR ANTHRACYCLINE-
INDUCED CARDIOTOXICITY
Cardiac complications were ﬁrst reported a few years
after the introduction of daunorubicin (3). In 1979, a
dose-toxicity curve was generated by plotting the
incidence of heart failure (deﬁned by clinical signs
and symptoms such as shortness of breath, neck vein
distension, S3 gallop, cardiomegaly, hepatomegaly,
or pericardial effusion) against the total anthracycline
dose used in many studies (4). Heart failure in-
cidences were 3%, 7%, and 18% in patients who had
received a cumulative dose of 400, 550, or 700 mg/m2
of doxorubicin, respectively. Therefore, oncologists
usually limited the cumulative anthracycline dose
to #550 mg/m2 (5). The introduction of cardiac im-
aging technology that allows detection of heart fail-
ure or even asymptomatic left ventricular (LV)and the yTexas Heart Institute, Houston, Texas. This
exas and the Moon Shot Program of the University of
ed that they have no relationships relevant to the
14, accepted June 10, 2014.
TABLE 1 Anthracycline Regimens in the Most Widely Used Protocols for
4 Types of Cancer
Type of Cancer Anthracycline Regimens Other Considerations
Breast cancer Doxorubicin 50–60 mg/m2 
4–6 cycles
Epirubicin 75–100 mg/m2 
4–8 cycles
Increased cardiotoxicity with
trastuzumab (11)
Bolus over 15 min
Sarcoma Doxorubicin 75–90 mg/m2 
6–8 cycles
Continuous infusion over 48–72 h or
bolus over 15 min þ dexrazoxane
Lymphoma Doxorubicin 40–50 mg/m2 
6–8 cycles
Continuous infusion over 48–72 h or
bolus over 15 min
Pediatric leukemia Doxorubicin 30 mg/m2 
10 cycles
Bolus over 30 min  dexrazoxane
AB BR E V I A T I O N S
AND ACRONYM S
ACE = angiotensin-converting
enzyme
ALL = acute lymphoblastic
leukemia
ARB = angiotensin receptor
blocker
DNA = deoxyribonucleic acid
FDA = U.S. Food and Drug
Administration
LV = left ventricular
LVEF = left ventricular
ejection fraction
ROS = reactive oxygen species
Tn = troponin
Top = topoisomerase
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939dysfunction led to the realization that incidence of
anthracycline-induced cardiotoxicity was higher than
previously estimated. In 2003, heart failure in-
cidences of 5%, 16%, and 26% were estimated for
cumulative doxorubicin doses of 400, 500, and
550 mg/m2, respectively (6), resulting in a modiﬁca-
tion to limit the cumulative anthracycline dose to 400
to 450 mg/m2.
Cardiac biopsy has been used to evaluate cardiac
damage in patients who received anthracycline
treatment, with morphological changes graded by the
Billingham system (7). This system assesses the
severity of cardiotoxicity using the degree of myoﬁ-
brillar loss or vacuolization. Some patients exhibited
morphologic changes with a cumulative dose of as
low as 200 mg/m2 (8). However, cardiac biopsy is not
routinely performed in current practice because of its
invasiveness.
Detecting troponin leakage in the peripheral blood
during or after anthracycline treatment positively
correlated with cardiac event rate and is a good, less
invasive alternative to biopsy for identifying cardiac
injury from anthracycline treatment. Troponin is
detectable in some patients as early as the end of the
ﬁrst anthracycline administration cycle (9); thus,
there is no safe cut-off point for anthracycline-
induced cardiotoxicity.
Anthracycline-induced cardiomyopathy has been
classiﬁed as early or late onset using a cutoff of 1 year
after anthracycline treatment (10). Cumulative in-
cidences of cardiac events peaked at 1 year after
anthracycline treatment (11,12). The actual incidence
of late cardiotoxicity is difﬁcult to ascertain because
of a lack of good studies. The multicenter Childhood
Cancer Survivor Study reported that additional cancer
treatment or other cardiovascular risk factors
might play an important role in causing late-onset
cardiomyopathy (13). This study also reported that
cardiovascular risk factors, such as hypertension,
diabetes, dyslipidemia, and obesity, are signiﬁcantly
higher in cancer survivors than in the healthy popu-
lation (13).
MECHANISMS OF ANTHRACYCLINE-INDUCED
CARDIOTOXICITY
Previously, the most widely accepted hypothesis
for anthracycline-induced cardiomyopathy was the
generation of excess reactive oxygen species (ROS)
by electron exchange between the anthracycline
quinone moiety and oxygen molecules and other
cellular electron donors (14). Anthracyclines also
form complexes with iron that undergo redox cycling
and generate oxygen radicals (15). Although in vivoand in vitro studies conﬁrmed increased ROS
production in cardiomyocytes after anthra-
cycline therapy, neither antioxidants nor iron
chelation prevented cardiomyopathy (16,17).
Topoisomerase (Top) 2b was recen-
tly revealed as the key mediator of
anthracycline-induced cardiotoxicity (18).
Top2 unwinds deoxyribonucleic acid (DNA)
strands during DNA replication, transcrip-
tion, or recombination (19). In humans, there
are 2 types of Top2 enzymes: Top2a and
Top2b (20). Top2a, found predominantly in
proliferating cells, is required for DNA repli-
cation and is considered the molecular
basis of anthracycline’s tumoricidal activity
(21). In contrast, Top2b is present in all
quiescent cells, including cardiomyocytes
(22). Top2 inhibition by anthracycline causes
double-stranded breaks in DNA, which can lead to
cardiomyocyte death (18).
Activation of p53 and the apoptotic pathway are
implicated in doxorubicin-induced cardiotoxicity (23).
Top2b is required for p53 activation in response
to anthracycline-induced DNA damage in car-
diomyocytes (18), whereas anthracycline-induced
ROS production is due to a reduction in antioxidant
enzyme gene transcription, which is also Top2b-
dependent (18). Doxorubicin also reduces expression
of uncoupling proteins 2 and 3, which regulate mito-
chondrial ROS production (24). Furthermore, Top2b
and anthracycline profoundly reduce peroxisome
proliferator-activated receptor-g coactivator 1-a and
peroxisome proliferator-activated receptor-g coac-
tivator 1-b, which are critical for mitochondrial
biogenesis (18). These ﬁndings suggest that Top2b
initiates anthracycline-induced cardiotoxicity (Central
Illustration). Most importantly, Top2b deletion from
the heart protects mice from anthracycline-induced
cardiomyopathy, which strongly implicates Top2b
as the primary mediator of anthracycline-induced
CENTRAL ILLUSTRATION Mechanism of Anthracycline-Induced Cardiotoxicity
Doxorubicin disrupts the normal catalytic cycle of topoisomerase (Top) 2b, causing
deoxyribonucleic acid (DNA) double-stranded breaks. It further changes the tran-
scriptome, leading to defective mitochondrial biogenesis and increase in reactive oxygen
species (ROS). As a result, cardiomyocytes showed myoﬁbrillar disarray and vacuolization.
In the inset, dexrazoxane was shown to bind to Top2b to prevent anthracycline binding.
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940cardiotoxicity (25). Other mechanisms may amplify
this effect. For example, hemochromatosis accumu-
lates iron, which ampliﬁes the ROS response during
anthracycline treatment (26).
GENETIC TESTING. Because cardiomyocyte-speciﬁc
Top2b deletion prevents anthracycline-induced car-
diotoxicity in mice (18), low cardiac Top2b expression
would be similarly expected to prevent cardiotoxicity
in patients. Peripheral blood leukocyte Top2b was
investigated as a surrogate biomarker for individual
susceptibility to anthracycline-induced cardiotoxicity
(27). Top2b levels were compared between 21
anthracycline-sensitive patients (decreased left ven-
tricular ejection fraction [LVEF] $10% from baseline
and LVEF <50%, despite receiving a cumulative
doxorubicin dose #250 mg/m2) and 15 anthracycline-
resistant patients (received a cumulative doxoru-
bicin dose $450 mg/m2 with LVEF $50%). Top2bwas signiﬁcantly higher in the anthracycline-
sensitive group than in the resistant group (0.4 
0.28 ng/mg vs. 0.23  0.1 ng/mg, p ¼ 0.026). Top2b
levels in the anthracycline-resistant group were all
below a 0.5 ng/mg cutpoint. Although conﬁrmation
requires larger prospective studies, these results
suggest that Top2b levels might be useful to stratify
patients for cardiotoxicity risk from anthracyclines.
Although Top2b is the primary mediator for
anthracycline-induced cardiomyopathy, other genes
might also have an inﬂuence. Iron accumulation can
amplify the ROS response to anthracycline exposure
(26). Therefore, patients with higher tissue iron con-
centrations, as in hereditary iron metabolism disor-
ders, have an elevated risk of cardiac damage.
Hemochromatosis gene C282Y carriers had a greater
myocardial injury risk than noncarriers (28). In a study
of single nucleotide polymorphisms of selected genes
involved in anthracycline transport or ROS produc-
tion, human nicotinamide adenine dinucleotide
phosphate oxidase variant rs1883112 was associated
with risk of chronic anthracycline-induced cardiotox-
icity (29). Prospective studies are needed to validate
these genetic markers for clinical application.
PRIMARY PREVENTION STRATEGIES
Two approaches for primary prevention of
anthracycline-induced cardiotoxicity are: 1) reduce
cardiotoxic potency by administering via continuous
infusion, liposome encapsulation, or using a less car-
diotoxic derivative (e.g., epirubicin or idarubicin);
and 2) use a cardioprotective agent (e.g., dexrazoxane)
in conjunction with treatment. Other investigated
agents include beta-blockers, angiotensin-converting
enzyme (ACE) inhibitors, and angiotensin receptor
blockers (ARBs) (Table 2).
CONTINUOUS INFUSION. Various anthracycline
schedules were evaluated in early clinical trials,
including 1 bolus dose every 3 weeks, 3 divided doses
every week, or 3 divided doses given 3 consecutive
days every 3 weeks. Endomyocardial biopsies
revealed that divided doses cause signiﬁcantly less
damage than bolus doses (30). Moreover, patients
who received divided doses tolerated a higher cu-
mulative doxorubicin dose. Tumor response rates and
overall survival rates among the groups did not
signiﬁcantly differ, and the weekly schedule offered a
longer duration of response than the bolus dose (30).
Whereas peak plasma level determines the severity
of cardiotoxicity, antitumor efﬁcacy corresponds to
the area under the plasma distribution curve (31).
Pharmacodynamics and pharmacokinetics studies
in animal models demonstrated that although
TABLE 2 Primary Prevention for Anthracycline-Induced Cardiotoxicity
Prevention Strategy Cost* Comments
Continuous doxorubicin
infusion (48–72 h)
$67/50 mg† Effective in cardioprotection in sarcoma and lymphoma, but not in the pediatric population
Liposomal doxorubicin $2,851/50 mg FDA-approved for ovarian cancer, AIDS-related Kaposi sarcoma, and multiple myeloma,
after failure of at least 1 prior therapy
Dexrazoxane $362/500 mg FDA-approved only for women with metastatic breast cancer who received at least
300 mg/m2 doxorubicin and need additional doxorubicin to maintain tumor control
ACEI/ARB/b-blockers $4/month Unknown whether they were cardioprotective or simply changed hemodynamics
*2014 Walmart pharmacy prices. †May be higher, depending on hospital stay or infusion pump care costs.
ACEI ¼ angiotensin-converting enzyme inhibitor; AIDS ¼ acquired immune deﬁciency syndrome; ARB ¼ angiotensin receptor blocker; FDA ¼ U.S. Food and Drug
Administration.
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941anthracycline concentrations in tumor tissue were
the same with continuous or bolus administration,
anthracycline concentration in the heart was higher
with the bolus dose, leading to higher clinical car-
diotoxicity (31). Increasing infusion duration clearly
reduced cardiotoxicity without compromising onco-
logical efﬁcacy (32), but an infusion lasting longer
than 96 h is associated with higher incidence of sto-
matitis and a prolonged need for an infusion pump
and indwelling catheter. Continuous doxorubicin
infusion over 48 to 72 h is widely used in sarcoma or
lymphoma patients.
In children with acute lymphoblastic leukemia
(ALL), continuous doxorubicin infusion is no more
cardioprotective than a bolus dose (33). Participants
who received either treatment had similar echocar-
diographic measurements in all parameters at 8-year
follow-up, which were signiﬁcantly worse in both
groups than at baseline (33), perhaps due to different
responses in children’s developing hearts.
LIPOSOMAL DOXORUBICIN. Another strategy to
reduce cardiotoxicity from conventional anthracy-
clines is to use liposomal encapsulation, which
modiﬁes pharmacokinetics and tissue distribution
without compromising antitumor efﬁcacy (34). Active
doxorubicin is trapped within the internal aqueous
compartment by the ion gradient difference. Whereas
liposomal doxorubicin is thought to be restricted to
inside the vessel wall of organs with tight capillary
junctions (such as the heart), it has been shown to
more readily penetrate through tumor vasculature,
which is more fragile and permeable than healthy
tissue (34). Thus, doxorubicin’s anticancer properties
are preserved with less cardiotoxicity.
Two types of liposomal doxorubicin are used clin-
ically: pegylated (Doxil, Janssen, Titusville, New
Jersey) or nonpegylated, of which the pegylated
version is more widely used in the United States.
Pegylation involves covalent attachment of surface-
bound methoxypolyethylene glycol to the liposomalphospholipid bilayer. This masks liposomes from
the mononuclear phagocyte system, lowering their
antigenicity and increasing their half-lives (35).
Because of its cost (Table 2), liposomal doxorubicin is
not widely used, and it is only approved by the U.S.
Food and Drug Administration (FDA) in ovarian can-
cer, acquired immune deﬁciency syndrome–related
Kaposi sarcoma, and multiple myeloma after failure
of at least 1 prior therapy (36).
DEXRAZOXANE. Dexrazoxane is the only FDA-
approved cardioprotective agent for anthracycline-
induced cardiotoxicity (37). It is an effective
cardioprotective agent against anthracyclines in a
variety of cancer types in children and adults (38,39).
Dexrazoxane’s ability to chelate iron was previously
thought to be the primary mechanism of car-
dioprotection (40). However, other iron chelators,
such as deferasirox or ICRF-161, do not provide car-
dioprotection (17,41). Lyu et al. (42) demonstrated
that dexrazoxane changes Top2’s conﬁguration to a
closed-clamp form through tight binding to Top2’s
ATP-binding sites, thus preventing anthracyclines
from binding to the Top2 complex (Central
Illustration).
Two multicenter breast cancer studies (clinical
studies 088001 and 088006) demonstrated dexra-
zoxane’s cardioprotective efﬁcacy (43,44). More than
500 patients with advanced breast cancer undergoing
anthracycline therapy were randomized to receive
either placebo or dexrazoxane. A cardiac event was
deﬁned as an LVEF decline $10% from baseline and
below the institution’s normal limit, an LVEF
decline $20% to at least 5% below the institution’s
normal limit, or development of heart failure. Hazard
ratios of placebo to dexrazoxane for cardiac events
were 2.63 (95% conﬁdence interval: 1.61 to 4.27,
p < 0.001) in the 088001 trial and 2.00 (95% conﬁ-
dence interval: 1.01 to 3.96, p ¼ 0.038) in the 088006
trial, clearly establishing dexrazoxane’s efﬁcacy
in preventing cardiac damage from anthracycline
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zoxane might interfere with anthracycline’s anti-
tumor efﬁcacy (44). In the 088001 trial, the
dexrazoxane arm had a lower response rate; however,
times to progression and survival rates were not
signiﬁcantly different (44). Of note, this study was
not replicated by other clinical trials (44), and animal
studies suggest that dexrazoxane synergizes with
anthracycline (45,46). The FDA approved dexra-
zoxane only for women with metastatic breast cancer
who need additional doxorubicin to maintain tumor
control after they received at least 300 mg/m2 of
doxorubicin (37).
Multiple trials have demonstrated dexrazoxane’s
efﬁcacy for primary prevention of anthracycline-
induced cardiotoxicity in children. More than 200
children with ALL were randomized to receive doxo-
rubicin 30 mg/m2 (cumulative dose 300 mg/m2) with
or without dexrazoxane (38). Blinded troponin (Tn) T
measurements were obtained at multiple time points
before, during, and after doxorubicin infusion. At the
end of the course, TnT levels were elevated in only
20% of children who received doxorubicin plus
dexrazoxane and in 47% of those in the doxorubicin
group (38). At 5-year follow-up, LV fractional
shortening and end-systolic dimension were similar
to those of normal children in the dexrazoxane
group but were worse than normal children in the
doxorubicin-only group (38).
Consistent with another retrospective study iden-
tifying female sex as an independent risk factor for
anthracycline-induced cardiotoxicity (47), reduced
LV fractional shortening was greater in girls than in
boys in the doxorubicin-only group across a 5-year
period (38). Moreover, dexrazoxane provides greater
cardioprotection for girls than for boys (38). FiveTABLE 3 Summary of b-Blocker and/or ACE Inhibitor Studies for Prim
First Author (Ref. #) Medication Patients
Kalay et al. (54) Carvedilol 12.5 mg daily vs.
placebo
50 (25/25
Georgakopoulos et al. (55) Metoprolol‡ vs. enalapril‡ vs.
placebo§
125 (42/43
Kaya et al. (53) Nebivolol 5 mg daily vs.
placebok
45 (27/18)
Bosch et al. (52) Enalapril‡ þ carvedilol‡ vs.
no treatmentk
90 (45/45
*Numbers in parentheses represent the numbers of patients in intervention and control/p
(p < 0.05). ‡Medications titrated as tolerated. §Medications started on the ﬁrst day of ch
before the ﬁrst chemotherapy cycle and continued for 6 months.
ACE ¼ angiotensin-converting enzyme; LVEF ¼ left ventricular ejection fraction; TnI ¼years after treatment, girls who received doxorubicin
with dexrazoxane had better fractional shortening
and a better end-diastolic thickness-to-dimension
ratio than those who received doxorubicin alone (38).
Animal studies suggest that hormonal status or body
fat percentage might cause the higher incidence of
cardiotoxicity found in girls (48). Although the reason
for its potency in girls is unknown, dexrazoxane
clearly provides long-term cardioprotection without
compromising anthracycline’s antitumor efﬁcacy.
With a median 8.7-year follow-up interval, event-free
survival rates were similar in patients who received
concurrent dexrazoxane and in those who received
doxorubicin alone (76% vs. 77%, p ¼ 0.99) (38).
Another controversy is the potential risk of
increased secondary malignancy, which was re-
ported in 1 study that added dexrazoxane to the
standard pediatric Hodgkin lymphoma regimen (49).
At 4-year follow-up, 8 patients in the dexrazoxane
arm developed secondary malignancy: 6 with acute
myeloid leukemia/myelodysplastic syndrome, 1 with
thyroid carcinoma (within the radiation ﬁeld), and 1
with osteosarcoma. If only acute myeloid leukemia/
myelodysplastic syndrome patients are considered,
the 2 arms did not differ signiﬁcantly (p ¼ 0.152) (49).
Two other studies of childhood ALL reported no dif-
ferences in secondary malignancy incidence between
dexrazoxane and placebo groups at 5- or 10-year
follow-up (50,51). Taken together, dexrazoxane is
unlikely to increase secondary malignancy risk.
BETA-BLOCKERS, ACE INHIBITORS, OR ARBS. Beta-
blockers, ACE inhibitors, and ARBs were evaluated in
randomized controlled trials for primary prevention
of anthracycline-induced cardiotoxicity (Table 3).
LVEF dropped signiﬁcantly after chemotherapy in
placebo or control groups, but not in interventionary Prevention of Anthracycline-Induced Cardiotoxicity
*
Follow-Up,
Months Results
) 6 Placebo: LVEF 68.9%/ 52.3%†
Carvedilol: LVEF 70.5%/ 69.7%
/40) 31 Cardiotoxicity incidence not statistically different
among 3 groups
No difference in echocardiographic parameters
among 3 groups at 12 months
6 Placebo: LVEF 66.6%/ 57.5%†
Nebivolol: LVEF 65.6%/ 63.8%
) 6 Control: LVEF 64.6%/ 57.9%†
Enalapril þ carvedilol: LVEF 63.3%/ 62.9%
TnI levels not signiﬁcantly different between
2 groups (p ¼ 0.59)
lacebo groups, respectively. †Statistically signiﬁcant between baseline and 6 months
emotherapy and continued throughout the study. kMedications started within 1 week
troponin I.
TABLE 4 Primary and Secondary Prevention Strategies
Clinical Setting Primary Prevention
Level of
Evidence*
Class of
Recommendation*
High-risk proﬁle from genetic testing Dexrazoxane
Liposomal doxorubicin
Continuous infusion
C IIb
Breast cancer (metastatic
>300 mg/m2)†
Dexrazoxane A I
Sarcoma‡ Dexrazoxane
Continuous infusion
A IIa
High-risk pediatric ALL§ Dexrazoxane A IIa
All patients receiving
anthracycline
b-blockers, ACEI, ARB C IIb
Secondary Prevention
Abnormal strain/LV function
 elevated cardiac biomarkers
b-blockers, ACEI, ARB B IIa
*According to American College of Cardiology Foundation/American Heart Association guideline criteria (65).
†Metastatic breast cancer patients requiring doxorubicin >300 mg/m2. ‡To receive doxorubicin >450 mg/m2.
§Patients age <12 months or 10 to 18 years; white blood cell count $50,000 cells/ml; or have T-cell phenotype,
presence of anterior mediastinal mass, or any lymphoblasts in a cerebrospinal ﬂuid sample.
ALL ¼ acute lymphoblastic leukemia; LV ¼ left ventricular; other abbreviations as in Table 2.
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943groups. Despite these declines, LVEFs remained
>50% (52–54). The major limitation of these studies is
the short-term (5 to 6 months) follow-up. Whether
beneﬁcial hemodynamic effects or primary protection
were responsible for these results is unclear. Over a
median 31-month follow-up period (the longest of
4 studies), no differences in echocardiographic pa-
rameters or heart failure incidence were observed
during doxorubicin treatment in lymphoma patients
randomized to receive metoprolol, enalapril, or
nothing (55). Another trial monitored TnI, the best
cardiac injury marker, during anthracycline therapy.
TnI leakage did not differ signiﬁcantly between the
control and intervention groups (4 patients vs.
7 patients, p ¼ 0.59) (52). In summary, whether
beta-blockers, ACE inhibitors, or ARBs are useful in
primary prevention is uncertain.
SECONDARY PREVENTION STRATEGIES
DETECTION. Cardiac injury from anthracycline ther-
apy is detected as LVEF changes that are measured
by echocardiography, multigated acquisition scans,
or magnetic resonance imaging (56–58). Echocardio-
graphic strain imaging has recently emerged as a
promising method for detection of cardiotoxicity
prior to LV dysfunction (57). Cardiotoxicity is deﬁned
as an LVEF decline of $5% to <55% with heart
failure symptoms or an asymptomatic decrease of
LVEF $10% to <55% (59). Factors inﬂuencing LVEF in
patients receiving anthracycline-containing regimens
include ﬂuid overload, sepsis, ischemic heart disease,
or other chemotherapy drugs.
Biomarkers are often used to identify patients with
early clinical signs of cardiotoxicity. Although the
peak value and duration of troponin elevation are
closely correlated with the degree of LV dysfunction,
the optimal time for blood sampling is unknown (9).
Troponin combined with LV systolic strain provided
better sensitivity and speciﬁcity (57) than other bio-
markers tested in prospective studies, such as brain
natriuretic peptide and N-terminal pro-brain natri-
uretic peptide (60,61).
BETA-BLOCKERS OR ACE INHIBITORS. Several studies
examined beta-blockers or ACE inhibitors for second-
ary prevention in high-risk patients after anthracy-
cline treatment; however, each study deﬁnedhigh-risk
features differently. One enalapril trial enrolled
patients with troponin leaks within 72 h after high-
dose chemotherapy (62). In this trial, the enalapril
group displayed signiﬁcantly higher LVEF than the
control group at 1-year follow-up, and signiﬁcant
LVEF drops occurred in 43% of control patients (>10%
to LVEF <50%) and in none of the enalapril patients(62). An observational study evaluated the efﬁcacy of
enalapril þ carvedilol in preventing deterioration of
LV function in patients with LVEF #45%, although
it lacked a control group. They found that LVEF
recovery was more likely with early initiation of an
ACE inhibitor and beta-blocker after completion of
anthracycline treatment (63). A small, retrospective
study in childhood cancer survivors questioned
whether ACE inhibitors improve long-term outcomes
of anthracycline-induced cardiomyopathy (64). In this
study, progressive improvements in echocardio-
graphic parameters after enalapril initiation did not
persist after 6 years of treatment; all patients either
required heart transplant or experienced cardiac-
related death (64), perhaps due to late initiation of
treatment.
SUMMARY
The ideal primary prevention protocol would involve
genetic susceptibility testing for markers such as
Top2b or hemochromatosis gene C282Y. However,
these genetic tests have not yet been validated in
prospective clinical trials and cannot be recom-
mended for general use at present. Both American
College of Cardiology Foundation/American Heart
Association and European Society of Cardiology
guidelines support the use of dexrazoxane to reduce
the occurrence and severity of anthracycline-induced
cardiotoxicity (65,66). However, questions regarding
antitumor effects or secondary malignancy limit
dexrazoxane’s wider use. New clinical trials to
expand the clinical indications for dexrazoxane
are crucial. Current recommendations for primary
prevention are to treat high-risk patients with
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infusion (Table 4).
Clinicians should be alerted to early signs of
anthracycline-induced cardiotoxicity by a combina-
tion of biomarker and imaging studies. Guidelines
developed through expert consensus recommend the
frequency and modality of testing for secondary
prevention (59). Standard heart failure treatment
should generally be initiated with the earliest
detection of cardiotoxicity (66) (Table 4).
Although there are ample primary or secondary
prevention opportunities, deﬁnitive clinical studiesdemonstrating efﬁcacy are lacking. These gaps should
be ﬁlled with carefully planned, multi-institutional
studies. We look forward to the days when patients
can be treated with anthracycline without worrying
about cardiotoxicity.
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